Daehan Nupharm Co.,Ltd. (KOSDAQ:054670)

Daehan Nupharm Statistics

Total Valuation

Daehan Nupharm has a market cap or net worth of KRW 92.21 billion. The enterprise value is 155.75 billion.

Market Cap	92.21B
Enterprise Value	155.75B

Important Dates

The next estimated earnings date is Tuesday, December 2, 2025.

Earnings Date	Dec 2, 2025
Ex-Dividend Date	Dec 29, 2025

Share Statistics

Daehan Nupharm has 14.04 million shares outstanding.

Current Share Class	14.04M
Shares Outstanding	14.04M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	39.26%
Owned by Institutions (%)	0.40%
Float	8.24M

Valuation Ratios

The trailing PE ratio is 8.48.

PE Ratio	8.48
Forward PE	n/a
PS Ratio	0.46
PB Ratio	0.71
P/TBV Ratio	0.72
P/FCF Ratio	n/a
P/OCF Ratio	9.70
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.28, with an EV/FCF ratio of -3.60.

EV / Earnings	14.32
EV / Sales	0.77
EV / EBITDA	9.28
EV / EBIT	12.40
EV / FCF	-3.60

Financial Position

The company has a current ratio of 1.61, with a Debt / Equity ratio of 0.73.

Current Ratio	1.61
Quick Ratio	1.04
Debt / Equity	0.73
Debt / EBITDA	5.44
Debt / FCF	-2.19
Interest Coverage	7.35

Financial Efficiency

Return on equity (ROE) is 8.57% and return on invested capital (ROIC) is 4.10%.

Return on Equity (ROE)	8.57%
Return on Assets (ROA)	3.59%
Return on Invested Capital (ROIC)	4.10%
Return on Capital Employed (ROCE)	7.18%
Revenue Per Employee	884.17M
Profits Per Employee	47.71M
Employee Count	228
Asset Turnover	0.88
Inventory Turnover	2.95

Taxes

In the past 12 months, Daehan Nupharm has paid 2.80 billion in taxes.

Income Tax	2.80B
Effective Tax Rate	20.48%

Stock Price Statistics

The stock price has decreased by -6.49% in the last 52 weeks. The beta is 0.35, so Daehan Nupharm's price volatility has been lower than the market average.

Beta (5Y)	0.35
52-Week Price Change	-6.49%
50-Day Moving Average	6,767.20
200-Day Moving Average	7,064.65
Relative Strength Index (RSI)	44.19
Average Volume (20 Days)	30,570

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Daehan Nupharm had revenue of KRW 201.59 billion and earned 10.88 billion in profits.

Revenue	201.59B
Gross Profit	93.45B
Operating Income	13.18B
Pretax Income	13.68B
Net Income	10.88B
EBITDA	17.40B
EBIT	13.18B
Earnings Per Share (EPS)	n/a

Balance Sheet

The company has 31.08 billion in cash and 94.61 billion in debt, giving a net cash position of -63.54 billion or -4,526.95 per share.

Cash & Cash Equivalents	31.08B
Total Debt	94.61B
Net Cash	-63.54B
Net Cash Per Share	-4,526.95
Equity (Book Value)	129.44B
Book Value Per Share	n/a
Working Capital	41.24B

Cash Flow

In the last 12 months, operating cash flow was 9.50 billion and capital expenditures -52.75 billion, giving a free cash flow of -43.25 billion.

Operating Cash Flow	9.50B
Capital Expenditures	-52.75B
Free Cash Flow	-43.25B
FCF Per Share	-3,081.44

Margins

Gross margin is 46.36%, with operating and profit margins of 6.54% and 5.40%.

Gross Margin	46.36%
Operating Margin	6.54%
Pretax Margin	6.79%
Profit Margin	5.40%
EBITDA Margin	8.63%
EBIT Margin	6.54%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 100.00, which amounts to a dividend yield of 1.52%.

Dividend Per Share	100.00
Dividend Yield	1.52%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	12.90%
Buyback Yield	n/a
Shareholder Yield	1.52%
Earnings Yield	11.80%
FCF Yield	-46.90%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Daehan Nupharm has an Altman Z-Score of 2.01 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.01
Piotroski F-Score	5